ACP Journal Club. Annual screening with CA-125 and transvaginal ultrasonography did not reduce ovarian cancer incidence or mortality.

摘要

Question Does screening with serum cancer antigen 125 (CA-125) and transvaginal ultrasonography (TVUS) reduce ovarian cancer mortality? Methods Design: Randomized controlled trial (Prostate, Lung, Colorectal, and Ovarian [PLCO] cancer screening trial). ClinicalTrials.gov NCT00002540. Allocation: Concealed. Blinding: Blinded (assessors of cause of death).* Follow-up period: 13 years (median 12.4 y). Setting: 10 screening centers in the USA. Patients: 68 557 women 55 to 74 years of age (65% < 65 y) without a history of bilateral oophorectomy or previous ovarian, lung, or colorectal cancer.